Type 2 diabetes treatments: how treatment is chosen, step by step, in current guidelines
Type 2 diabetes treatment starts with nutrition, activity and education, adds medicines chosen by heart, kidney and weight goals, and moves to injections such as GLP-1 drugs and insulin when needed. This is the sequence the 2026 ADA Standards describe.
At a glance
- Topic
- Type 2 diabetes medicines
- Topic guide
- Diabetes medications
- Sources
- 10 cited, numbered at the bottom; each [n] mark links to its source
- Updated
Type 2 diabetes treatments follow a sequence in the 2026 American Diabetes Association (ADA) Standards of Care: set an individual A1C goal, build nutrition, physical activity and self-management education, choose a first medicine by heart, kidney and weight needs, add or adjust medicines when the goal is not met, and use injectables, first GLP-1 drugs and then insulin, when tablets are not enough [1]. Treatment is adjusted for life, not completed.
This guide sits under diabetes medications, which compares every drug class in one table. It describes how clinicians decide; it is not advice on what any reader should take.
Diabetes mellitus type 2 treatment, step by step
The order below is the one the 2026 Standards set out; each step is revisited at every review.
| Step | What happens |
|---|---|
| 1. Set the goal | An A1C below 7% is the goal for many non-pregnant adults, set higher or lower for the person [2] |
| 2. Lifestyle and education | Medical nutrition therapy, at least 150 minutes a week of moderate-to-vigorous activity for most adults, and diabetes self-management education [3] |
| 3. First medicine | Chosen by heart disease, heart failure, kidney disease, weight, hypoglycemia risk and cost; metformin when none of those points elsewhere [1] |
| 4. Add or adjust | Further medicines are added or changed when the goal is not met; early combination therapy is an option at diagnosis [1] |
| 5. Injectables | A GLP-1 receptor agonist or tirzepatide is preferred to insulin when an injectable's stronger effect is needed [1] |
| 6. Insulin | Started when glucose stays above goal on other drugs, or early when glucose is very high or symptoms are present; combined with a GLP-1 drug when used [1] |
The steps overlap. Many people start a medicine at diagnosis alongside the lifestyle step, and a person with heart failure or kidney disease is offered an SGLT2 inhibitor whatever their A1C. Treating type II diabetes in this framework is less a ladder than a set of conditions checked again at each visit.
Lifestyle treatment: food, activity and weight
The ADA's behaviour section covers individualised nutrition from a dietitian, regular physical activity, reduced sitting time, sleep and stopping tobacco, alongside formal diabetes self-management education and support [3]. No single diet pattern is required; the Standards accept several eating patterns that reduce calories and refined carbohydrate.
Weight loss has the largest effect. In the DiRECT trial in UK primary care, a structured programme of low-calorie formula diet followed by food reintroduction took 46% of participants off all diabetes medicines with an A1C below 6.5% at 12 months, against 4% with usual care [4]. Remission depended on how much weight was lost, which the type 2 diabetes remission guide covers in full.
How the first diabetes medicine is chosen
The 2026 Standards ask which conditions a person has before asking which A1C they have [1]:
- Atherosclerotic heart disease or high risk: a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit.
- Heart failure: an SGLT2 inhibitor; for heart failure with preserved ejection fraction and obesity, semaglutide injection or tirzepatide are also listed.
- Chronic kidney disease: an SGLT2 inhibitor, with a GLP-1 receptor agonist as an option.
- Weight management as a goal: a GLP-1 receptor agonist or tirzepatide.
- None of the above: metformin is the usual first tablet; it is effective, inexpensive and does not cause hypoglycemia on its own.
The randomised evidence explains the order. A network meta-analysis of 453 trials found no difference in deaths or vascular events between treatments in people at low cardiovascular risk, while specific GLP-1 receptor agonists and SGLT2 inhibitors reduced death in people at increased risk [5]. Metformin vs insulin compares the two oldest options, and Jardiance for type 2 diabetes covers the SGLT2 inhibitor most often chosen for heart and kidney protection.
Type 2 diabetes injections: GLP-1 drugs, tirzepatide, insulin and amylin
Injectable diabetes medicines are a later step for most people, and GLP-1 drugs now come before insulin.
| Group | How often | Where it sits in treatment | Examples |
|---|---|---|---|
| GLP-1 receptor agonists | Usually once a week, pen under the skin [6] | Preferred injectable before insulin; lower weight; low hypoglycemia risk alone | Semaglutide (Ozempic), dulaglutide |
| Dual GIP/GLP-1 agonist | Once a week; injected separately from insulin, never mixed [7] | Largest A1C and weight effect of the non-insulin drugs | Tirzepatide (Mounjaro) |
| Basal insulin | Once or twice a day | Added when other drugs do not reach the goal, or early when glucose is very high | Glargine, degludec, detemir, NPH |
| Mealtime insulin | Before meals | Added to basal insulin when post-meal glucose stays high | Lispro, aspart, glulisine, regular |
| Amylin analogue | Before major meals, separate from insulin [8] | Only for people already using mealtime insulin | Pramlintide (Symlin) |
The ADA prefers a GLP-1 receptor agonist or tirzepatide to insulin when a person needs the greater glucose-lowering effect of an injection, and when insulin is used it recommends combining it with one of them for better glucose, weight and hypoglycemia results [1]. When tirzepatide is started on top of a sulfonylurea or insulin, its label tells prescribers to consider reducing those doses because the combination raises the risk of low blood sugar [7].
The next injectable may combine two hormones. In REIMAGINE 3, adults with type 2 diabetes already on basal insulin who added once-weekly CagriSema lowered A1C by 2.33 points against 0.66 on placebo over 40 weeks, with no severe hypoglycemia [9]. CagriSema is not approved; new diabetes medications tracks it and the other drugs in late trials.
Injectable insulin for type 2 diabetes: when it is used
Insulin is graded the most potent glucose-lowering medicine [1], and it works where other drugs fall short. In the 2026 Standards it is used in three situations: when glucose stays above goal despite other medicines; early, at or near diagnosis, when glucose or A1C is very high or there are symptoms such as weight loss and thirst; and during acute illness, surgery or hospital stays. Early insulin can often be reduced or stopped once glucose comes down and other medicines take over.
Its costs are hypoglycemia and weight gain, the two reasons the Standards pair it with a GLP-1 receptor agonist where possible [1]. Insulin and sulfonylureas are the classes the Standards single out for hypoglycemia risk [2]; the hypoglycemic drugs guide compares the classes on that measure.
Is there a cure for type 2 diabetes? What remission means
The research term is remission: A1C below 6.5% for months without glucose-lowering medicine.
No medicine or programme is called a cure in the evidence, because blood sugar can rise again. What trials measure is remission. In DiRECT, 46% of the intervention group were in remission at 12 months [4], and 36% still were at 24 months, against 3% of the usual-care group [10]. Among people who kept off at least 10 kg, 64% were in remission at two years [10].
Remission is most likely early in the disease and with large, sustained weight loss, which is why intensive weight management and metabolic surgery are the main routes studied. Type 2 diabetes remission covers the definition and the trials, and prediabetes medication covers the stage before diagnosis.
More in this topic
This guide is part of Diabetes medications.
- Prediabetes medication: what the prevention trials showedNo medicine is approved in the US specifically for prediabetes. Metformin has the longest record, cutting diabetes onset by 31% in the Diabetes Prevention Program, less than lifestyle change did; semaglutide and tirzepatide showed larger effects in people with obesity.
- Metformin vs insulin: how much each lowers A1C, and how they differMetformin lowers A1C by about 1.1 percentage points on its own; insulin can lower it as far as needed but brings low blood sugar and weight gain. Here is what the trials measured for each, and when the 2026 ADA Standards use one, the other, or both.
- Hypoglycemic drugs: the glucose-lowering classes, and the medicines that raise blood sugarHypoglycemic drugs, also called antihyperglycemic or antidiabetic agents, are the medicines that lower blood sugar. Here they are classified in one table with the classes that can cause hypoglycemia, and a second table lists common drugs that increase blood sugar.
- Jardiance for type 2 diabetes: how empagliflozin works and what its trials foundJardiance is empagliflozin, a once-daily SGLT2 inhibitor tablet, not insulin. It lowers A1C by roughly 0.7 to 0.9 points against placebo, and its heart and kidney trials earned it approvals for heart failure and chronic kidney disease as well as diabetes.
- New diabetes medications: what has been approved recently, and what is comingThe new type 2 diabetes medications approved in 2026, from the Ozempic pill to two once-weekly insulins, the late-stage drugs behind them, and a plain answer to what is replacing metformin.
- Glucose pills: glucose tablets for lows versus pills that lower blood sugarGlucose tablets raise blood sugar to treat a low; diabetes pills lower it. The two meanings, the ADA's 15-15 rule, grams per tablet, and which diabetes pills make lows more likely.
- Can type 2 diabetes be cured? What remission trials showThere is no cure for type 2 diabetes, but trials show remission: normal HbA1c off all glucose-lowering drugs. What diet, surgery and GLP-1 studies achieved, and how long it lasted.
Questions people ask
What is the first treatment for type 2 diabetes?
Lifestyle change and self-management education start for everyone, usually alongside a first medicine. Metformin is the usual first tablet unless heart disease, heart failure, kidney disease or weight goals point to an SGLT2 inhibitor or GLP-1 drug [1].
When do people with type 2 diabetes need injections?
When tablets do not keep A1C at goal, or earlier if a GLP-1 drug is chosen for heart or weight reasons. The ADA prefers a GLP-1 receptor agonist or tirzepatide before insulin, and uses insulin early when glucose is very high or symptoms are present [1].
Can type 2 diabetes go away?
It can go into remission. In DiRECT, 36% of people in a structured weight-management programme had an A1C below 6.5% without diabetes medicines after two years [10]. Remission is not described as a cure because glucose can rise again.
Is insulin the last resort in type 2 diabetes?
No. It is used whenever other medicines are not enough, and sometimes early to bring very high glucose down quickly; it is often combined with a GLP-1 drug [1].
Sources
Numbered in the order they are first cited. The bracketed numbers in the text link straight to these.
- 19. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.
pmid-41358900· · peer-reviewed - 26. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
pmid-41358894· · peer-reviewed - 35. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026.
pmid-41358898· · peer-reviewed - 4Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
pmid-29221645· · peer-reviewed - 5Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
pmid-32598218· · peer-reviewed - 6OZEMPIC (semaglutide) injection prescribing information
fda-ozempic-label-2026· · regulatory - 7MOUNJARO (tirzepatide) injection prescribing information
fda-mounjaro-label-2025· · regulatory - 8SYMLIN (pramlintide acetate) injection prescribing information
fda-symlin-label-2019· · regulatory - 9
- 10
Last reviewed and what changed
- · Written: the type 2 diabetes treatment sequence in the ADA 2026 Standards, lifestyle, first-medicine choice, injectables (GLP-1, tirzepatide, insulin, amylin), when insulin is used, and remission evidence from DiRECT.